Sophiris Bio Inc (SPHS) Holdings Boosted by Geode Capital Management LLC

Geode Capital Management LLC raised its holdings in Sophiris Bio Inc (NASDAQ:SPHS) by 14.9% during the fourth quarter, HoldingsChannel reports. The firm owned 243,523 shares of the biopharmaceutical company’s stock after buying an additional 31,579 shares during the period. Geode Capital Management LLC’s holdings in Sophiris Bio were worth $202,000 as of its most recent SEC filing.

Separately, Virtu Financial LLC acquired a new stake in shares of Sophiris Bio during the 4th quarter valued at approximately $30,000. Institutional investors own 8.53% of the company’s stock.

SPHS stock opened at $0.78 on Thursday. The company has a current ratio of 2.00, a quick ratio of 2.65 and a debt-to-equity ratio of 2.93. The company has a market cap of $24.17 million, a P/E ratio of -1.50 and a beta of 2.81. Sophiris Bio Inc has a 12-month low of $0.75 and a 12-month high of $4.05.

Sophiris Bio (NASDAQ:SPHS) last posted its quarterly earnings results on Thursday, May 9th. The biopharmaceutical company reported ($0.08) earnings per share (EPS) for the quarter, beating the Thomson Reuters’ consensus estimate of ($0.10) by $0.02. Sell-side analysts expect that Sophiris Bio Inc will post -0.38 earnings per share for the current year.

SPHS has been the topic of several research reports. Piper Jaffray Companies dropped their price target on Sophiris Bio to $5.00 and set an “overweight” rating on the stock in a research report on Wednesday, March 13th. HC Wainwright dropped their price target on Sophiris Bio from $10.00 to $3.50 and set a “buy” rating on the stock in a research report on Thursday, March 14th. Finally, Maxim Group set a $6.00 price target on Sophiris Bio and gave the company a “buy” rating in a research report on Friday, May 10th.

TRADEMARK VIOLATION NOTICE: “Sophiris Bio Inc (SPHS) Holdings Boosted by Geode Capital Management LLC” was first posted by Slater Sentinel and is owned by of Slater Sentinel. If you are accessing this article on another publication, it was illegally stolen and republished in violation of US & international trademark & copyright law. The legal version of this article can be read at

Sophiris Bio Company Profile

Sophiris Bio, Inc, a clinical-stage biopharmaceutical company, focuses on the development of products for the treatment of urological diseases. The company's primary product candidate is PRX302, which is in Phase III clinical trial for treatment of lower urinary tract symptoms of benign prostatic hyperplasia (BPH), as well as for the treatment of localized low to intermediate risk prostate cancer.

Recommended Story: Different Options Trading Strategies

Want to see what other hedge funds are holding SPHS? Visit to get the latest 13F filings and insider trades for Sophiris Bio Inc (NASDAQ:SPHS).

Institutional Ownership by Quarter for Sophiris Bio (NASDAQ:SPHS)

Receive News & Ratings for Sophiris Bio Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Sophiris Bio and related companies with's FREE daily email newsletter.